Novartis

Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Novartis building

Biotech

Large Cap

News

Health Care

Movers

Trading Ideas

General

RGLS

Offerta cash con premio elevato per azienda biofarmaceutica specializzata in malattie renali. Pagamento aggiuntivo legato a milestone.

Novartis acquisisce società americana e il titolo schizza del 133%!

General Motors

Equities

Markets

SANM

SBUX

Attesa per i conti di big dell&#39;automotive e delle bevande. Focus anche su tech, farmaceutica e ristorazione tra risultati e guidance.

General Motors, Coca-Cola e altri 3 titoli sotto i riflettori oggi: cosa aspettarsi

Novartis AG

Envista Holdings Corporation Common Stock

Envista Holdings Corp

NEVADA SUNRISE METALS CRP by NEVADA SUNRISE METALS CORP.

Nevada Sunrise Metals Corp

NOVUS HLDGS LTD SHS by NOVUS HLDGS LTD SHS

Novus Holdings Ltd

Press Releases

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Barbara Weber, M.D., Elected to ITM Supervisory Board

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

NYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

ARVN

ATNM

BNTX

ONCY

RLAY

RVMD

TNGX

TSX:ONC

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Novartis

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO